Sign in
Taking people in United StatesPhase 2

Tests a stem cell transplant method for blood cancers

Tests a T cell-depleted stem cell transplant in people with leukemia.

Key facts

Who runs it
Masonic Cancer Center, University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Registry title
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Status
Recruiting
Phase
Phase 2
People taking part
70 people, planned
Started
11 May 2023
Expected to end
30 Nov 2030
Type of study
Interventional, 8 groups
Treatments tested
  • Fludarabine
  • Busulfan
  • Melphalan
  • Rituximab
  • Levetiracetam
  • Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
  • Thymoglobulin
  • Cyclophosphamide
Record updated
6 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adults aged 60 or younger with blood cancers such as acute leukemia or high-risk myelodysplasia. It tests a stem cell transplant with T cells removed.

Age
60 years or younger
Sex
All sexes can join
Disease stage
Blood cancer confirmed by tissue tests: acute myeloid leukemia, acute lymphoblastic leukemia or lymphoma, or myelodysplasia (IPSS INT-2 or high risk, or refractory anemia with severe low blood counts, transfusion need, or high-risk cytogenetic or molecular features). Good daily function is also needed (Karnofsky 70% or more, or Lansky 50% for those 16 or younger), with adequate organ function.
Earlier treatment
People who have had any earlier autologous or allogeneic transplant cannot join.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Active uncontrolled infection within 1 week of starting preparative therapy
  • Known HIV-positive, or active hepatitis B or C with detectable virus by PCR
  • Any earlier autologous or allogeneic transplant
  • CML blast crisis, or active central nervous system cancer

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Histological confirmation of hematological malignancies
  • Acute leukemias
  • Acute Myeloid Leukemia (AML) and related precursor neoplasms
  • Favorable risk AML is defined as having one of the following:
  • Acute lymphoblastic leukemia (ALL)/lymphoma
  • Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features
  • Age 60 years of age or younger at the time of consent
  • Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age
  • Adequate organ function

Who cannot take part

  • Any prior autologous or allogeneic transplant
  • Active uncontrolled infection within 1 week of starting preparative therapy
  • Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR
  • Active central nervous system malignancy
  • Pregnant or breastfeeding
  • CML blast crisis

Where in United States

  • University of Minnesota/Masonic Cancer CenterMinneapolis, United StatesContact: Margaret MacMillanTaking people

About the trial

What the trial wants to find out

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety/feasibility study of the investigational procedure/product.

The 8 groups in the trial

  • Arm 1A: Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI Regimen, Closed to AccrualTreatment being tested

    Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Treatment: Fludarabine, Rituximab, Levetiracetam, and Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells

  • Arm 2A: Fludarabine (flu), Busulfan (bu), Flu/Bu Regimen, Closed to AccrualTreatment being tested

    Patients will be treated on the most medically appropriate regimen with a preference for Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Treatment: Fludarabine, Busulfan, Rituximab, and Levetiracetam

  • Arm 3A: Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients OnlyTreatment being tested

    Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia. , Closed to Accrual

    Treatment: Fludarabine, Busulfan, Melphalan, Rituximab, and Levetiracetam

  • Arm 1B: ATG, Fludarabine (flu), Total Body Irradiation (TBI), Flu/TBI RegimenTreatment being tested

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Treatment: Fludarabine, Rituximab, Levetiracetam, and Thymoglobulin

  • Arm 2B: ATG, Fludarabine (flu), Busulfan (bu), Flu/Bu RegimenTreatment being tested

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/Flu/BU/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Treatment: Fludarabine, Busulfan, Rituximab, Levetiracetam, and Thymoglobulin

  • Arm 3B: ATG, Fludarabine (flu), Busulfan (bu), Melphalan (Mel) Regimen for Pediatric Patients OnlyTreatment being tested

    ATG/Flu/Bu/Mel will the preference for patients with JMML or infants with leukemia.

    Treatment: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, and Thymoglobulin

  • Arm 4B: ATG, Busulfan (BU), Cyclophosphamide (CY)Treatment being tested

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/BU/CY Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Treatment: Busulfan, Rituximab, Levetiracetam, Thymoglobulin, and Cyclophosphamide

  • Arm 5B: ATG, Cyclophosphamide (CY), Total Body Irradiation (TBI)Treatment being tested

    Patients will be treated on the most medically appropriate regimen with a preference for ATG/CY/TBI Arm followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.

    Treatment: Rituximab, Levetiracetam, Thymoglobulin, and Cyclophosphamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Plain-language title
Tests a stem cell transplant method for blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 April 2026